Compelling epidemiologic and molecular data indicate that genes play a primary role in determining who is at risk for developing multiple sclerosis (MS), how the disease progresses, and how someone responds to therapy. The genetic component of MS etiology is believed to result from the action of allelic variants in several genes. Their incomplete penetrance and moderate individual effect probably reflects epistatic interactions, post-transcriptional regulatory mechanisms, and significant environmental influences. Equally significant, it is also likely that locus heterogeneity exists, whereby specific genes influence susceptibility and pathogenesis in some individuals but not in others. With the aid of novel analytical algorithms, the combined study of genomic, transcriptional, proteomic, and phenotypic information in well-controlled study groups will define a useful conceptual model of pathogenesis and a framework for understanding the mechanisms of action of existing therapies for this disorder, as well as the rationale for novel curative strategies.
Introduction
Multiple sclerosis (MS, [MIM 126200]) is a severe disorder of the central nervous system (CNS) characterized by chronic inflammation, myelin loss, gliosis, varying degrees of axonal and oligodendrocyte pathology, and progressive neurological dysfunction ( Figure 1 ). 1 MS exhibits several characteristics that are common to demyelinating diseases, including a relative high frequency, tendency to strike young adults, and diversity of manifestations. These disorders also share features of inflammation and selective destruction of CNS myelin; the peripheral nervous system is spared. MS is the most common cause of acquired neurological disability arising between early to middle adulthood affecting approximately 2 million people worldwide and more than 400 000 individuals in the United States. Prevalence is influenced by family history, ethnicity, age, and geography. Women are affected twice as often as men, suggesting that gender is an additional risk factor. Fifteen years after diagnosis, fewer than 20% of patients have no functional limitation, 50-60% require assistance when ambulating, and 75% are not employed. Despite important advances in therapeutics for MS, none of the currently available disease-modifying drugs have been found to significantly alter the long-term prognosis of the disease. The partial, negligible or deleterious effects that some approaches have demonstrated in clinical practice, despite being successful at the bench, reflect the complex molecular interactions operating in MS and limitations of the current working models and hypotheses for disease pathogenesis.
MS clusters with the so-called complex genetic diseases, a group of common disorders characterized by modest disease risk heritability and multifaceted gene-environment interactions. The genetic component in MS is suggested by familial aggregation of cases and the high incidence in some ethnic populations (particularly those of northern European origin) compared with others (African and Asian groups), irrespective of geographic location. High-frequency rates are found in Scandinavia, Iceland, and the British Isles (about 1-2 in 1000), and the countries inhabited by their descendants. Lower frequencies are found among southern Europeans. The disease is uncommon among Samis, Turkmen, Uzbeks, Kazakhs, Kyrgyzis, native Siberians, North and South Amerindians, Chinese, Japanese, African blacks, and New Zealand Maori. 2 According to some observers, this characteristic geographical distribution implicates a pathogen that is not ubiquitously distributed. MS is, in general, a disease of temperate climates with a population prevalence that decreases with decreasing latitude. Even within the United States, distinctions exist in the prevalence of MS between populations living north and south of the 37th parallel. However, this prevalence pattern can also be explained at least in part, by the geographical clustering of northern Europeans and their descendants. Further, the overall distribution of MS in Europe, showing many exceptions to the previously described north-south gradient, requires more explanation than simply an environmental relationship. 3 The high risk among Sardinians, Parsis, and Palestinians, and the observation of resistant ethnic groups residing in high-risk regions, as for example Gypsies in Bulgaria 4 or Japanese in the United States, 5, 6 support the hypothesis that the differential risk observed in different population groups results primarily from genetic susceptibility or resistance. Evidence of risk heritability in the form of familial recurrence has long been known. [7] [8] [9] The degree of familial aggregation can be determined by estimating the ratio of the prevalence in siblings vs the population prevalence of the disease (l s ). 10 For MS, l s is between 20 (0.02/0.001) and 40 (0.04/0.001). Half-sibling, 7 adoptee, 11 and spouse 12 risk assessment studies performed in Canada appear to confirm that genetic, and not environmental factors are primarily responsible for the familial clustering of cases. However, an intriguing association with month of birth was observed in the Canadian familial cases, reflecting perhaps an interaction between genes and an environmental factor operating during gestation or shortly after birth. 13 Concordant sibs tend to share age of symptom onset rather than year of onset, and second and third degree relatives of MS patients are also at an increased risk. Furthermore, twin studies from different populations consistently indicate pairwise concordance (20-40% in identical twin pairs compared to 2-5% in like-sex fraternal twin pairs) providing additional evidence for a genetic etiology in MS. 14, 15 Interestingly, twin concordance appears to exhibit, at least in the Canadian series, gender dimorphism. 16 Finally, parent-of-origin effects may also influence both disease susceptibility and outcome, [17] [18] [19] and concordance in families for early and late clinical features has been observed as well, suggesting that in addition to susceptibility, genes may influence disease severity or other aspects of the clinical phenotype. [20] [21] [22] Altogether, neither the recurrence familial rate nor the twin concordance supports the presence of a Mendelian trait. Modeling of the available data predicts that the MS-prone genotype results from multiple interacting polymorphic genes, each exerting a small or at most a moderate effect to the overall risk.
MS genomics
Genetic studies of patients with MS in the previous decade were dominated by three whole genome 10 cM microsatellites-based screens performed in multipleaffected families ascertained in the US, UK, and Canada. [23] [24] [25] Follow-up screenings in confirmatory and additional data sets have been completed as well (at least one additional large linkage study of 830 sib pairs using over 4500 single-nucleotide polymorphism or 'SNP' markers is in progress). Together, these studies identified approximately 60 genomic regions potentially involved in disease susceptibility, consistent with the long-held view that MS is a polygenic disorder. However, total or even predominant replication between the different screens was not obvious. This is in part due to the limited power of the data sets, incomplete genomic maps available at the time the studies were performed resulting in poor average information extraction, unknown genotyping error rates, low statistical thresholds and the strategy of reporting all 'hits' of potential linkage, recognizing that false positives would be generated. It is also possible that the study design in each case underestimated the confounding influence of disease heterogeneity and the limitations of parametric methods of statistical analysis. Meta-analyses of the raw data from eleven published studies (over 700 multicase MS families) has refined the linkage map (Table 1) , 26 but linkage exceeding the threshold for genome-wide statistical significance was only detected in the MHC region on chromosome 6p21. 3 , confirming yet again, the known association with the HLA class II DR2 haplotype (HLA-DRB1*1501-DQA1*0102-DQB1*0602). Interestingly, an effect of HLA-DR2 copy number on disease risk has also been detected; [27] [28] [29] this observation was to a certain degree unexpected because if HLA-DRb molecules confer susceptibility in MS by presenting an encephalitogenic peptide, then a dominant effect would be anticipated. In the animal model of MS, experimental autoimmune encephalomyelitis or EAE, a single copy of a diseaseassociated MHC haplotype, when present in the context of an appropriate genetic background, is generally sufficient for the induction of susceptibility.
RR-MS SP-MS
Attempts to identify the primary susceptibility gene in the HLA region have not provided consensus. The identification of the true predisposing gene or genes within the DR2 haplotype has been made more complex by the extensive linkage disequilibrium (LD) across the region, and by the presence of many other potential candidate genes with roles in immune function within this region. When the effect of DRB1*1501 is removed from the DR2 haplotype, inconclusive evidence against 30 or in favor 31, 32 of a primary role for DQB1*0602 in MS susceptibility has been reported. There is also debate as to the role of non-HLA genes mapping to this region. 33 Results suggesting that genes of interest exist within the class III 34, 35 and/or telomeric to the class I 36-40 regions have been reported as well. The imminent availability of genetic maps defining haplotype bins in the HLA extended region 41, 42 will provide a useful reference and tools to identify the true disease gene or genes for MS operating within this superlocus.
As patterns of genomic disequilibrium differ between populations, the most direct and practical approach to resolve this complex genetic obstacle will be to scrutinize and compare a large number of MS haplotypes in wellcharacterized data sets from distinct populations. For example, some combinations in cis of DRB1 and DQB1 alleles are unique in African-Americans. Specifically, the DRB1*1501, DQB1*0602 haplotype does not display the rigidity and high degree of LD that is characteristic of northern Europeans. In a recent study of DRB1 and DQB1 alleles and haplotypes in a large and wellcharacterized African-American MS cohort, a selective association with HLA-DRB1*15 was revealed, indicating a primary role for the DRB1 locus in MS independent of DQB1*0602. 43 It is then likely that HLA-DRB1 constitutes the centromeric boundary of the class II DR-DQ association in MS. African-American patients also exhibited an unusual high degree of allelic heterogenity as disease association at the DRB1 locus was found for DRB1*1501, DRB1*1503, and DRB1*0301 alleles. The haplotypic features of the DRB1*1501-DQB1*X (non 0602) and DRB1*1503-positive chromosomes indicated an older African origin for the HLA-associated MS susceptibility gene(s), predating the divergence of human ethnic groups, rather than being solely due to genetic admixture with people of European descent.
HLA-DRB1*1501 has a relative low frequency in Africa. Positive selection for this allele appears to have occurred in Europeans but not in Africans, and although the factors that drove this selection, presumably some infectious pathogen, are unknown, one possible consequence was a heightened susceptibility to MS in Europe, a disorder almost nonexistent in Africa. Compared to Europeans-Americans, African-Americans are at lowrisk for MS, 5, 44 supporting the presence of genetic risk factors that occur at higher frequency in Europeans. As the sections of the genome in African-Americans inherited from their European or African ancestors have only had an average of six generations of recombination, extended LD is present, and non-MHC disease genes are potentially amenable to identification through admixture mapping using reasonable numbers of ancestry informative genetic markers that are readily available. 45, 46 A primary role for HLA-DRB1 in susceptibility to MS is consistent with a pathogenesis model, which involves a T-cell mediated autoimmune response against the 85-99 peptide of myelin basic protein (MBP). [47] [48] [49] [50] The crystal structure of DRb1501 differs from other non DR2-related DRb molecules in that aromatic residues in the ligand are preferred in the large hydrophobic P4 pocket of the peptide binding domain. 51 For MBP, this pocket is primarily occupied by the aromatic side chain Phe92, acting as an important primary anchor and accounting for its high-affinity binding to the HLA-DRa0101/ DRb1501 heterodimer ( Figure 2 ). The polymorphic residue at DRb 71 is also critically important in creating the necessary space for Phe92 of MBP, and Ala at this position has only been observed for DR15 alleles (DRB1*1501-DRB1*1506) and DRB1*1309. HLA-DRB1*1501, DRB1*1503 and DRB1*0301 alleles on the other hand, all share a critical Val residue at position 86, Score were obtained from the meta-analysis of the sibling pair families only. Meta-analysis based on a total of 719 families. 26 Evidence of linkage exceeding the threshold for genomewide statistical significance was only observed in the MHC region on chromosome 6p21. However, although no other region of the genome showed an NPL score of this magnitude, four additional regions with NPL scores exceeding 2.0 were identified. The most negative NPL score was just À1.8 (at the q telomere of ch.13).
where the HLA-DRb chain is also polymorphic, and can encode either Val or Gly. DRbVal86 at the base of the P1 pocket results in a smaller pocket than that observed for DR1 and DR4 (Gly), for example, influencing not only binding and presentation of a number of self-antigens including MBP, but also DRab dimer stability. [51] [52] [53] The Val86/Val86 genotype has been implicated in association studies in Swedish and Australian MS populations. 30, 54 Overall, however, the mechanisms underlying the genetic associations of HLA alleles with MS are not yet fully understood. An interesting alternative hypothesis proposes that microchimerism (MC) may also increase the risk for developing autoimmune disease. MC refers to the stable presence in an individual of non-self cells, usually stem cells or their progeny. Factors influencing the long-term persistence of these cells are not well defined, but are likely to include pregnancy history and feto-maternal HLA compatibility. It has been suggested that a high HLA similarity between MC and host cells could actually deceive the host immunoregulatory pathways resulting in an immune response against selfcomponents. 55 Intriguingly, mothers with systemic sclerosis were nine times more likely to have given birth to an HLA-DRB1 compatible child before disease onset than control mothers. 56 The risk was even greater (19-fold) if the child was DRB1 compatible due to homozygosity. 55 Large family-based disease studies incorporating reproductive history and HLA data are critical to determine whether histocompatibility of mothers and offspring are correlated with MS risk. Using family data, the proportion of total genetic susceptibility explained by the HLA locus in MS was estimated; at the lower end, under an additive model it could explain as little as 15% and at the upper end under a multiplicative genetic model the HLA association can explain as much as 60% of the genetic etiology. 57 In either case, much of the genetic effect in MS remains to be explained, but there is no consensus on which are the best-supported non-MHC regions in the genome. Unfortunately, the direct testing by association of possibly relevant candidate genes, identified by speculation based upon concepts of pathogenesis, has been also unproductive for gene identification in this disease. Recently reported associated genes such as NOS2a, 58 
IL4R,
59 CD24, 60 TAC1, 61 CCLs, 62 and MHC2TA 63 constitute promising leads but remain to be replicated. Surprisingly, genes found to be associated with multiple autoimmune diseases such as CTLA4 and PTN22
64,65 do not appear to play a major role in MS, indicating a fundamentally different disease pathogenesis. Progress in developing affordable high-throughput genotyping technology and a better understanding of the complex structure encoded within the human genome [66] [67] [68] suggest that the tools may finally be at hand to achieve the elusive goal of whole-genome association studies. 69 Although most SNPs are likely to be neutral with no phenotypic consequences, some may mark the 'causative' sequence difference contributing to disease susceptibility and/or resistance. A small case-control study of 10 000 SNPs in MS was recently reported. 70 Association studies of this type harbor great potential for complex disorders, but a number of very important challenges, including how to interpret results obtained from large numbers of statistical tests, and how to detect biologically meaningful interactions between polymorphisms that confer disease risk, will need to be overcome. Furthermore, to correctly interpret large-scale SNP data we must discern to what extent the SNPs under analysis are located within segmental duplications, 71 inversions, 72 or regions with loss of imprinting, 73 polymorphic genomic imbalances, 74 or resistant to X-inactivation. 75 Genetic heterogeneity in MS A noteworthy conceptual development in the understanding of MS genetics has been the recognition of locus heterogeneity, meaning that different genes can cause identical or similar forms of the disease in different individuals. In a study of 184 multicase US MS families, linkage and association to the HLA-DRB1 locus, and a strong association with the specific DR2 haplotype (DRB1*1501, DQB1*0602) was confirmed. 21 Remarkably, all the linkage information and evidence for association derived from the families in which DRB1*1501 was present in at least one nuclear member. No genetic effect of the HLA locus could be discerned in the clinically indistinguishable DRB1*1501-negative family set. In fact, the results excluded linkage for at least 20 cM around HLA-DRB1 in the DRB1*1501-negative families, providing strong evidence that heterogeneity at the HLA locus exists in MS.
Another example of HLA locus heterogeneity in MS is provided by studies in Japanese patients. In this group, one form of MS is characterized by disseminated CNS involvement and is associated with the HLA-DRB1*1501 haplotype whereas more restricted forms of disease in which optic nerve and or spinal cord involvement predominate and lesions are more severe and necrotizing, are not associated with HLA-DRB1*1501. 76 The strength of the association between primary progressive MS (PPMS) and HLA-DRB1*1501 is also uncertain. A number of small studies failed to show any association between PPMS and DRB1*1501, although a larger study from Northern Ireland appeared to show the association. 77 We recently studied HLA class II alleles in an MS data set carefully ascertained in Sicily, an island 3 km apart from continental Italy, with a population of just over 5 100 000, but unique demographic history and high MS prevalence and incidence. 78 Evidence for excess transmission to affected individuals was observed for HLA-DRB1*1501, DRB1*04, DQB1*02 and DQB1*0302 alleles but not for DQB1*0602. When HLA alleles were analyzed as haplotypes, we observed an excess transmission for the DRB1*04, DQB1*0302 haplotype. Overall, Sicilian patients share the HLA-DRB1*1501 susceptibility allele with patients living in continental Italy, but also display allelic heterogeneity, specifically a strong association with the HLA-DR4 haplotype. The HLA-DR3 haplotype observed in association with MS in neighboring Sardinia 38 was negative in Sicilians. However, HLA-DR3 may confer a low relative risk compared to HLA-DRB1*1501, and large data sets may be necessary to detect its effect. Interestingly, a dose effect for HLA-DR3 has also been proposed in MS cases and controls, 29 and confirmed in family studies (Barcellos et al, unpublished data) However, in contrast to HLA-DR2, the risk conferred by DR3 appears to be recessive, with two copies (DR3/DR3) significantly increasing risk, compared to no risk for DR3/DRX individuals.
The clinical thinking that MS is a single disorder with varied clinical manifestations and courses may be at odds with data derived from a variety of disciplinesclinical, pathologic, imaging, immunologic, and genetic-all suggesting that biologic diversity is an important feature of the MS syndrome. The implications of this heterogeneity are considerable because fundamentally distinct immunopathogenic mechanisms may be acting in different affected individuals. Progress in deciphering the MS genome is necessarily linked to a full description of heterogeneity at all etiological levels.
Susceptibility genes vs modifiers
Clinical symptoms in MS are extremely variable. The course may be relapsing-remitting or progressive, severe or mild, and involve the neuraxis in a widespread fashion or predominantly affect the spinal cord and optic nerve. Very little is known about the underlying cause of disease variability in MS, but is important to recognize that the aggregate contribution of germline genetic variants to the disease course may be quite modest. This is highlighted by observations that the clinical expression of MS may be different even between monozygotic twin siblings. Nevertheless, the demonstration of even a modest genetic effect of a known gene on the course of MS could represent a major therapeutic opportunity. A large number of studies have focused on the relevance of HLA variation to clinical features in MS with inconclusive findings. To date, HLA-DRB1*1501 has been reported to be associated with an earlier age of disease onset, female gender, severe, relapsing-remitting, and mild MS courses, 28, [79] [80] [81] [82] [83] or to have no influence on disease course. [84] [85] [86] [87] [88] [89] To assess the state of genotype-phenotype research in MS, we have identified from the literature a set of gene polymorphisms that have been reported to be significantly associated with phenotypic end points ( Table 2 ). The list omits many reports and probably includes type I errors due to small sample sizes. In addition, series are retrospective, some phenotypic end points are questionable or not validated, and the confounding effects of drug treatment and/or stratification have not been generally considered. Finally, the assessment of modifier effects has often been piggybacked upon candidate-gene susceptibility studies, further limiting their informativeness. Parenthetically, it may also be difficult to discriminate whether phenotypic diversity reflects etiological heterogeneity as suggested above, a modifying role of a specific gene, or some combination of the two. These caveats aside, the studies summarized in Table 2 highlight the range and scope of published reports suggesting genetic influences on the natural history of MS.
Genes and environmental factors
Epidemiological, twin concordance, clusters or outbreaks, and migration studies have been widely used to illustrate potential environmental influences on MS. Although the interpretation of most of these studies has been difficult, in part due to the small number of study participants in the individual reports, the results have been influential and do suggest a role for environmental factors in MS, and in some cases, the existence of critical time periods for exposure to putative environmental disease agents. A large number of environmental exposures have been investigated. Those include viral and bacterial infections, nutritional and dietary factors, well water consumption, exposure to animals, minerals, trauma due to accident or surgery, pollution, solar radiation, temperature, rainfall, humidity, chemical agents, metals, organic solvents, and various occupational hazards.
Spirochetes were claimed to be the cause of MS 90 years ago. This was a reasonable assumption given that syphilis can cause a relapsing/remitting CNS inflammatory disease with synthesis of oligoclonal immunoglobulins in the cerebrospinal fluid (CSF). Since then, more than 20 infectious agents, ranging from retroviruses to mycobacteria have been associated with MS onset and/ or relapses. Viruses are among the most frequently studied and biologically plausible putative infectious agents related to MS pathogenesis, and many have been proposed to be the causative MS agent. Prominent candidates have included measles, rubella, mumps, and the herpes viruses including Epstein-Barr virus (EBV), herpes simplex virus 1 and 2 and varicella zoster virus. Higher antibody titers against each of these have been detected in the serum and CSF samples of MS patients when compared to control individuals. Strong evidence for a role of EBV, in particular, has been indicated by epidemiologic 90 and laboratory studies. 91, 92 Similar to other autoimmune diseases, exposure to cigarette smoke has also emerged as a potential environmental risk factor for MS. In a recent prospective A high prevalence of DR2 was observed in patients with acute unilateral optic neuritis. Its presence was associated with increased odds for developing definite MS. The association was most apparent among patients with signal abnormalities on the baseline brain MRI 135 A number of small studies failed to show any association between PPMS and DR2, although a larger study from Northern Ireland appeared to show the association. Others suggested an association between PPMS and the HLA-DR4 haplotype although a post hoc analysis is consistent with an effect decreasing the risk for RRMS in HLA-DR4+ individuals, rather than increasing the risk for PPMS 22, 77, 88, 136, 137 Glutamic acid at position 71 or 74 in pocket 4 of DRb1 is associated with PPMS 138 CD24 6q21 ORF A/V 50% of CD24 V/V patients with expanded disability status scale 6.0 reached the milestone in 5 years, whereas the CD24 A/V and CD24 A/A patients did so in 16 and 13 years, respectively 60 ESR1 6q21.5 PvuII and XbaI RFLP The P allele-positive patients had a significantly higher progression of disability and a worse ranked MS severity score. The study also suggests an interaction between the ESR1 genotype and DR2 in women with MS. Esr1 and -2 appear to regulate the severity of clinical EAE 139, 140 PvuII RFLP The study suggests an interaction between the ESR1 genotype and DR2 in women with MS. Patients with the CNTFÀ/À genotype had significantly earlier onset (17 vs 27 years) with predominant motor symptoms 143 No correlation with age of onset, course, or severity 144 study, researchers defined a 60% greater incidence rate of MS in current smokers compared to never smokers. 93 Interestingly, the relative rate also increased significantly with cumulative exposure to smoking. However, most attempts to isolate the causative environmental trigger in MS have been largely unproductive and have failed to provide major insights into mechanisms of disease susceptibility and pathogenesis. This may be due to heterogeneity operating also at the level of causative factors. Whether the genotype dictates different forms of the same disease in response to a common causative agent or other trigger, or whether the genotype reflects different diseases with completely separate environmental causes is not known. The expectation that any single agent would have enough specificity and universality to account for all cases of a single disorder is unrealistic. On the other hand, the identification and confirmation of true environmental factors can lead to the discovery of important variation in relevant susceptibility genes such as cell membrane molecules serving as pathogen receptors, as well as base excision repair or detoxification enzymes.
Genetics in animal models
Experimental allergic (or autoimmune) encephalomyelitis (EAE) can be induced in a variety of animal species, including nonhuman primates, by immunization with myelin proteins or their peptide derivatives, as well as by adoptive transfer of CD4 þ activated cells specific for myelin components. 94, 95 A second, virally induced animal model for MS uses the Theiler's murine virus from the picorna family to induce brain inflammation and injury of the myelin sheath. When studied in genetically susceptible animals, immunization induces brain inflammation accompanied by varied signs of neurological disease, ataxia and paralysis, first in the tail and hind limbs, then progressing to forelimb paralysis and eventual death. EAE and MS share common clinical, histologic, immunologic and genetic features; hence, EAE is widely considered to be a relevant model for the human disease. The concept of susceptibility vs resistance in EAE is relative rather than absolute, as evidence demonstrates that modifications of the experimental protocol will induce detectable disease in strains previously considered resistant. Genetic studies in EAE have been informative in defining the complex interplay of multiple genes that can result in brain inflammation and demyelination. Furthermore, like MS, EAE is sensitive to environmental factors including age and season at immunization. 96, 97 The best characterized EAE susceptibility gene resides within the MHC on murine chromosome 17. 98 Induction and full clinical manifestations of EAE are strongly influenced by inherited polymorphisms of MHC class II region genes; certain MHC haplotypes are more permissive for EAE whereas others are more resistant.
The use of classic genetics and whole-genome screening in different strains has identified several additional genetic regions that contain QTLs conferring EAE susceptibility, including loci on chromosomes 2, 3, 7, 8, 15, 16, 17 (MHC in the mouse), 17 (distal to MHC) and 18. 99 Other regions have been implicated as containing disease-modifying genes affecting severity, course, duration and CNS pathology. All together 27 non-MHC have been identified. Interestingly, the linkage peaks are, in part, gender specific. 99 More recently, genetic control of CNS reparative traits in viral induced EAE (less axonal damage, progressive remyelination, and stabilization of motor function) was demonstrated highlighting the significant extent to which genetic factors can influence disease course. 100 These studies provide compelling evidence for the hypothesis that susceptibility to autoimmune demyelination is genetically determined. Similar to human diseases, a multiple-locus model is applicable; each locus may contribute to a specific stage of EAE pathology, although some loci are probably involved in several steps of the autoimmune process. 101 However, no locus seems to be an absolute requirement 
Functional genomics
During the process of lesion formation, lymphocyte activation and recruitment, extravasation and effector functions involve several cellular phenotypic changes triggered by specific gene expression pathways. Cytokines, adhesion molecules, growth factors, and other molecules, such as free radicals, proteases, vasoactive amines, and excitatory neurotransmitters, induce and regulate numerous critical cell functions in both, the inflammatory and neurodegenerative phases of MS. The comprehensive analysis of these cellular transcriptional programs, the transcriptome, both in the CNS and the periphery, could provide a molecular fingerprint of the pathogenic process and help identify the complete array of MS disease-genes. Low-and high-capacity microarray-based studies describing the MS lesion have been recently published. [102] [103] [104] Although difficult to compare due to differences in plaque activity, tissue harvesting, processing, and analysis, a common picture seems to emerge from these studies. 105, 106 An elevated transcriptional activity of inflammation-related genes is easily detected, particularly at the edge of active plaques. This is likely reflecting an active immune response in the lesions. Using a combination of large-scale expressed-sequencetags sequencing and microarray technology, we reported differentially expressed genes in active lesions and control brains from MS patients and EAE animals. 107 In that study, alpha B-crystallin, an inducible heat shock protein localized in the myelin sheath and a putative target for T cells in MS, 108 was identified as the most abundant transcript unique to MS plaques. The next five most abundant transcripts included those for prostaglandin D synthase, prostatic binding protein, ribosomal protein L17, and osteopontin. The expression of immunoglobulin genes showed differential regulation according to the stage of the plaque (ie a higher expression was observed in acute than in chronic silent lesions). Genes with decreased expression include those for several myelin components such as proteolipid protein, myelin associated glycoprotein, and myelin oligodendrocyte glycoprotein. This last finding may reflect not only the catabolic demyelinating process but also ineffective myelin repair.
Genetical genomics has recently been proposed as a novel approach that merges the power of two very different research methodologies. Here, gene expression levels are evaluated as potential QTL in linkage analyses (eQTL) using either microsatellite or SNP-based genetic maps. 109 Unlike classic linkage analysis in which a single (or a few) phenotypic traits are evaluated for statistical correlation against a genomic region, a very large number of gene expression values are considered as traits, and hence, thousands of LOD scores are calculated, extending de facto the definition of the phenotype. Using this approach, a gene expression pattern strongly associated with murine obesity was identified leading to the identification of four new QTL linked to this complex phenotype. 110 More recently, genetical genomics yielded the identification of regulatory networks affecting stem cell function, 111 blood pressure, 112 and some neural phenotypes. 113 In humans, analysis of genomically controlled variation in gene expression has also been reported 114 opening a promising venue for unraveling biological pathways in complex diseases.
Genetic variation and the clinical response to therapy in MS
Perhaps the most significant advance in MS therapeutics has been the approval of interferons. 115 Interferons are small inducible proteins secreted by nucleated cells in response to viral infection or other stimuli, and act in a paracrine fashion on other cells in their immediate vicinity. Overall, IFNb has been shown to decrease clinical relapses, reduce brain MRI activity, and possibly slow progression of disability. However, the effect of this treatment is partial, and a substantial amount of patients are not responders. Therapy has been associated with a number of adverse reactions, including flu-like symptoms, transient laboratory abnormalities, menstrual disorders, increased spasticity, and dermal reaction. Furthermore, the significance of long-term effects and impact on disease progression has not been determined. Hence, in the absence of predictive clinical, neuroradiological, and/or immunological markers of response, and given that 20-25% of patients have relatively benign forms of the disease, the question remains for neurologists to whom and when to recommend treatment, when side effects, inconvenience, and cost of the drug are significant.
The pharmacogenomic MS literature is relatively sparse, but a substantial effort is currently underway in different laboratories to directly address the question of genetic heterogeneity and the response to immunotherapy by analysis of the correlation between different genotypes and clinical response to therapeutic modalities. In recently published studies, for example, an effect of the HLA-DR2 haplotype was observed in MS patients treated with glatiramer acetate (Copaxone, an immune modulator) but not with IFNb. 89, 116 The analysis of eight SNPs in the interferon receptor genes failed to show significant evidence of pharmacogenomic influences. 117 More recently, we applied advanced data-mining and predictive modeling tools to a longitudinal gene expression data set generated from MS patients treated with IFNb in order to discover higher-order predictive patterns associated with treatment outcome. 118 We identified nine sets of gene triplets whose expression, when tested before the initiation of therapy, can predict favorable response to with up to 87% accuracy. Noteworthy, the genes in the top-scoring triplet were Caspase-2, Caspase-10, and FLIP, three apoptosis-related molecules. The second highest scoring triplet was that of Caspase 2, Caspase 3, and IRF4 (86.8%). Other high scoring triplets included IL4Ra and MAP3K1, in addition to other apoptotic molecules. Despite the relatively high predictive accuracy of these models, the functional link between genes and therapeutic effects of this drug is still unclear.
Conclusions
Compelling epidemiologic and molecular data indicate that genes play a primary role in determining who is at risk for developing MS. The genetic component of MS etiology is believed to result from the action of common allelic variants in several genes. Some loci may be involved in the initial pathogenic events, while others could influence the development and progression of the disease. Their incomplete penetrance and moderate individual effect probably reflects interactions with other genes, post-transcriptional regulatory mechanisms, and significant environmental and epigenetic influences. Equally significant, it is also likely that genetic heterogeneity exists, meaning that specific genes influence susceptibility and pathogenesis in some individuals with MS but not others.
The past few years have seen real progress in the development of laboratory and analytical approaches to study non-Mendelian complex genetic disorders and in defining the pathological basis of demyelination, setting the stage for the final characterization of the genes involved in MS susceptibility and pathogenesis. Largescale molecular explorations in human genetics are now virtually routine. The careful and methodic mining of genetic and gene expression data could lead to the identification of coregulated genes and characterization of genetic networks that underlie specific cellular processes. This complex organization is what ultimately defines biological function and, therefore, the disease phenotype.
Familial aggregation in MS was recognized prior to end of the 19 century but progress in understanding the role of genes MS has been slow, and appears to be beyond the grasp of any single research team. Given the complexity of the biological pathways leading to MS, tackling this problem in a meaningful and decisive manner requires the development of close and altruistic partnerships between research teams to achieve a critical mass of multidisciplinary expertise in different fields including neuropathology, human genetics, biostatistics, mathematics, genealogy, epidemiology, molecular biology, and informatics. With the aid of high-capacity technologies, the combined and integrative analysis of genomic, transcriptional, proteomic, and extensive phenotypic information, including environmental exposure data, will define a useful conceptual model of pathogenesis and a framework for understanding the mechanisms of action of existing therapies for this disorder, as well as the rationale for novel curative strategies.
